CRISPR Therapeutics AG
CRSP56.660USD
+0.400+0.71%
取引時間 （ET）15分遅れの株価
4.89B時価総額
損失額直近12ヶ月PER
詳細情報 CRISPR Therapeutics AG 企業名
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
企業情報
企業コードCRSP
会社名CRISPR Therapeutics AG
上場日Oct 19, 2016
設立日2013
最高経営責任者「CEO」Dr. Samarth Kulkarni, Ph.D.
従業員数393
証券種類Ordinary Share
決算期末Oct 19
本社所在地Baarerstrasse 14
都市ZUG
証券取引所NASDAQ Global Market Consolidated
国Switzerland
郵便番号6300
電話番号41415613279
ウェブサイトhttps://crisprtx.com/
企業コードCRSP
上場日Oct 19, 2016
設立日2013
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: 19 hours ago
更新時刻: 19 hours ago
株主統計
種類
株主統計
株主統計
比率
ARK Investment Management LLC
11.79%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Capital World Investors
3.33%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.50%
株主統計
株主統計
比率
ARK Investment Management LLC
11.79%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Capital World Investors
3.33%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.50%
種類
株主統計
比率
Investment Advisor
42.83%
Investment Advisor/Hedge Fund
18.49%
Hedge Fund
5.53%
Research Firm
4.10%
Venture Capital
3.64%
Individual Investor
1.69%
Bank and Trust
0.73%
Sovereign Wealth Fund
0.51%
Pension Fund
0.39%
Other
22.09%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
940
72.81M
84.30%
-1.94M
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
ARK Investment Management LLC
10.17M
11.77%
+1.19M
+13.29%
Mar 31, 2025
Capital International Investors
6.07M
7.03%
-2.67M
-30.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.80M
4.4%
-13.61K
-0.36%
Mar 31, 2025
Nikko Asset Management Americas, Inc.
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.41M
2.8%
-100.08K
-3.98%
Mar 31, 2025
State Street Global Advisors (US)
2.41M
2.79%
-80.26K
-3.22%
Mar 31, 2025
Two Sigma Investments, LP
1.99M
2.3%
+1.60M
+407.93%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.94M
2.25%
-282.75K
-12.72%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sun, Jul 6
更新時刻: Sun, Jul 6
銘柄名
比率
ARK Genomic Revolution ETF
8.52%
ARK Innovation ETF
4.63%
Global X Genomics & Biotechnology ETF
4.02%
AXS Green Alpha ETF
3.01%
Virtus LifeSci Biotech Products ETF
2.34%
WisdomTree BioRevolution Fund
1.95%
SPDR S&P Biotech ETF
1.46%
Direxion Daily S&P Biotech Bull 3X Shares
0.77%
Main Thematic Innovation ETF
0.72%
ProShares Ultra Nasdaq Biotechnology
0.48%
詳細を見る
ARK Genomic Revolution ETF
比率8.52%
ARK Innovation ETF
比率4.63%
Global X Genomics & Biotechnology ETF
比率4.02%
AXS Green Alpha ETF
比率3.01%
Virtus LifeSci Biotech Products ETF
比率2.34%
WisdomTree BioRevolution Fund
比率1.95%
SPDR S&P Biotech ETF
比率1.46%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.77%
Main Thematic Innovation ETF
比率0.72%
ProShares Ultra Nasdaq Biotechnology
比率0.48%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
